Over the years, pharmacovigilance centres have been involved in Medication Errors “ME” and preventability of Adverse Drug Reactions (ADRs). Following the Institute of Medicine’s report results in 1999, the patient safety concept increased to a high level of health care priority. Since then, data on this field are available particularly for developed countries. Unfortunately, there is a lack of data in low- and middle-income countries. For that purpose, the Centre Anti Poison et de Pharmacovigilance du Maroc “CAPM” has been involved in extending the role for National Pharmacovigilance centres to include ME and to disseminate findings internationally by conducting three studies. The results highlighted the ability of pharmacovigilance centres to detect and analyze ME and raised the need to develop and strengthen the role of pharmacovigilance centres in managing ME. Pharmacovigilance centres have the capacity for detecting and managing medication errors particularly when a dedicated organization dealing with patient safety is missing. To display these findings, a WHO guideline entitled reporting and learning systems for medication errors: the role of pharmacovigilance centres has been developed to enable pharmacovigilance centres, medication safety organizations and patient safety organizations to detect, analyze, and manage ME. The aim of our work is to present the role of pharmacovigilance centres in the detection and management of ME through Moroccan PV success stories.